Home › Upcoming votes › Lifecore Biomedical, Inc.
Prior-year votes at Lifecore Biomedical, Inc. →
The deadline as the proxy statement states it: “instructions detailed in the section of this proxy statement entitled "The Special Meeting-Voting Procedures", so long as your later-dated proxy is received by 11:59 p.m., Eastern Time, on December 22, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGARLifecore Biomedical, Inc.: past votes
Summary, checked against the proxy statement. Each point is backed by a passage of the filing, shown under the point; figures under “Last year’s votes” come from the company’s Form 8-K. Read the proxy statement before relying on it.
Special meeting to vote on the merger with affiliates of Webster Equity Partners, an advisory vote on merger-related executive pay, and a possible adjournment.
“will be canceled and cease to exist and be converted into the right to receive $6.28 per share in cash, without interest plus one (1) contingent value right per share (each, a "CVR").” Find it in the filing
“On September 27, 2026, the Company entered into an Agreement and Plan of Merger (as it may be amended or supplemented from time to time, the "merger agreement") with Lifecore Inc., a Delaware corporation ("Parent"), and Hazel Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub").” Find it in the filing
“As of September 27, 2026, the Conversion Amount represents an amount equal to $6.53 per share of common stock into which the Series A Preferred Stock would have been convertible as of such date.” Find it in the filing
“We cannot complete the merger unless the merger agreement proposal is approved by the affirmative vote (in person or by proxy) of the holders of a majority of the aggregate combined voting power of the outstanding shares of common stock and shares of Series A Preferred Stock (voting on an as-converted basis) entitled to vote thereon at the special meeting.” Find it in the filing
“The Board recommends you vote "FOR" the merger agreement proposal, "FOR" the advisory compensation proposal and "FOR" the adjournment proposal.” Find it in the filing
“such additional number of shares of common stock as is 10% of the number of PSUs underlying such PSU award at grant.” Find it in the filing
“on December 23, 2026, at 10:00 a.m. Central Time (unless the special meeting is adjourned or postponed), in a virtual-only meeting format.” Find it in the filing
Ballot read from the proxy statement and checked. As listed in Lifecore Biomedical, Inc.’s proxy statement, with the board’s recommendation on each item.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | MERGER AGREEMENT PROPOSAL | Board | For | — |
| 2 | ADVISORY COMPENSATION PROPOSAL | Board | For | — |
| 3 | ADJOURNMENT PROPOSAL Adjournment |
Board | For | — |
From Lifecore Biomedical, Inc.’s Form 8-K, filed October 31, 2025, for the meeting held October 29, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Katrina L. Houde | 90% | — |
| Elect Director: Humberto C. Antunes | 99.0% | — |
| Elect Director: Paul H. Johnson | 99.5% | — |
| Elect Director: Paul Josephs | 99.8% | — |
| Elect Director: Matthew E. Korenberg | 95% | — |
| Elect Director: Nelson Obus | 98% | — |
| Elect Director: Joshua E. Schechter | 89% | — |
| Elect Director: Jason Aryeh | — | — |
| Elect Director: Christopher S. Kiper | — | — |
| 2. The appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, | 99.9% | Approved |
| 3. The compensation paid to the Company's named executive officers (in the form of a non-binding, advisory vote), with votes | 99.0% | Approved |
The five managers that reported the most shares voted at Lifecore Biomedical, Inc.’s October 29, 2025 meeting, from their Form N-PX filings. This is how they voted then; it says nothing about how they will vote this time. Every manager’s vote.
| Item | WYNNEFIELD CAPITAL INC | Legion Partners Asset Management, LLC | 325 CAPITAL LLC | Vanguard | BlackRock |
|---|---|---|---|---|---|
| Elect Director: Katrina L. Houde | — | — | — | For | Against |
| Elect Director: Humberto C. Antunes | — | — | — | For | For |
| Elect Director: Paul H. Johnson | — | — | — | For | For |
| Elect Director: Paul Josephs | — | — | — | For | For |
| Elect Director: Matthew E. Korenberg | — | — | — | For | For |
| Elect Director: Nelson Obus | — | — | — | For | For |
| Elect Director: Joshua E. Schechter | — | — | — | For | Against |
| 2. The appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending | — | — | — | For | For |
| 3. The compensation paid to the Company's named executive officers (in the form of a non-binding, advisory vote), with v | For | — | For | For | For |
| PROPOSAL NO LONGER VALID | — | — | — | — | Abstain |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.